News - Phagenesis

Skip to main content Skip to footer

Home
About
News
Contact

Home
About
News
Contact

January, 2018

News

First PHAST-TRAC results were presented at ISC 2018

←
1
2
3
4

Phagenesis Headquarters
Unit 18 Enterprise House, Manchester Science Park, Manchester M15 6SE, United Kingdom

+44 (0)161 820 4525

[email protected]

Phagenesis operates from the UK, Germany, Austria and the United States

Terms and Conditions Privacy Policy Cookies Policy

Manufacturer; Phagenesis Ltd, Enterprise House, Manchester Science Park, Manchester, M15 6SE, UK

Indications for Use (Europe/UK/Switzerland): The Phagenyx System (EPSB3 Base Station and PNX-1000 catheter) is to be used for the treatment of neurogenic dysphagia in adult patients.
For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product.

Indications for Use (US): Phagenyx is a neurostimulation device delivering electrical stimulation to the oropharynx, to be used in addition to standard dysphagia care, as an aid to improve swallowing in patients with severe dysphagia post stroke.

Federal law in the US restricts this device to sale by or on the order of a physician. For a list of Contraindications and Side Effects please access the Phagenyx System User Guide provided with the product.

The content on this website is intended for healthcare providers and may not be approved for use in your specific region or country. Phagenesis is not responsible for any interactions or dealings you have via this website that do not comply with applicable laws and regulations in your jurisdiction. By continuing to use this website, you acknowledge and agree to the terms of this notice.